Ruggero Capra

17.0k total citations · 1 hit paper
146 papers, 5.4k citations indexed

About

Ruggero Capra is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Ruggero Capra has authored 146 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Pathology and Forensic Medicine, 46 papers in Oncology and 28 papers in Neurology. Recurrent topics in Ruggero Capra's work include Multiple Sclerosis Research Studies (99 papers), Polyomavirus and related diseases (44 papers) and Peripheral Neuropathies and Disorders (17 papers). Ruggero Capra is often cited by papers focused on Multiple Sclerosis Research Studies (99 papers), Polyomavirus and related diseases (44 papers) and Peripheral Neuropathies and Disorders (17 papers). Ruggero Capra collaborates with scholars based in Italy, United States and United Kingdom. Ruggero Capra's co-authors include Gıancarlo Comı, Flavia Mattioli, Massimo Filippi, Chiara Stampatori, Xavier Montalbán, Tracy Stites, Jean Pelletier, Bhupendra Khatri, Ana de Vera and Ludwig Kappos and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ruggero Capra

140 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

2010 1.6k citations Gıancarlo Comı, Ruggero Capra et al. profile →

Peers

Countries citing papers authored by Ruggero Capra

Since Specialization

Citations

This map shows the geographic impact of Ruggero Capra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruggero Capra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruggero Capra more than expected).

Fields of papers citing papers by Ruggero Capra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruggero Capra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruggero Capra. The network helps show where Ruggero Capra may publish in the future.

Co-authorship network of co-authors of Ruggero Capra

This figure shows the co-authorship network connecting the top 25 collaborators of Ruggero Capra. A scholar is included among the top collaborators of Ruggero Capra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruggero Capra. Ruggero Capra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Relapse‐Associated and Relapse‐Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Eras 2024 ·Annals of Neurology ·(unknown), Cinzia Cordioli, Alessio Signori, Francesca Bovis, Ruggero Capra, Maria Pia Sormani	5
2	SARS-CoV-2 antibodies in inflammatory neurological conditions: a multicentre retrospective comparative study 2023 ·Immunologic Research ·Cecilia Zivelonghi, Alessandro Dinoto, Sarosh R. Irani, Andrew McKeon, (unknown), Alessandro Padovani, Stefano Masciocchi, (unknown), Chiara Mancinelli, Ruggero Capra, Giorgia Teresa Maniscalco, Irene Volonghi, Ava Easton, Daniela Alberti, Gianluigi Zanusso, Salvatore Monaco, Gian Luca Salvagno, Giuseppe Lippi, Sérgio Ferrari, Sara Mariotto	0
3	NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders 2021 ·Multiple Sclerosis and Related Disorders ·Sara Mariotto, Matteo Gastaldi, Luisa Grazian, Chiara Mancinelli, Ruggero Capra, Romain Marignier, Daniela Alberti, Serena Zanzoni, Kathrin Schanda, Diego Franciotta, (unknown), Salvatore Monaco, Markus Reindl, Sérgio Ferrari, Alberto Gajofatto	20
4	Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study 2020 ·Neurotherapeutics ·Luca Prosperini, Chiara Mancinelli, Claudio Solaro, Viviana Nociti, Shalom Haggiag, Cinzia Cordioli, Laura De Giglio, Nicola De Rossi, Simonetta Galgani, Sarah Rasia, Serena Ruggieri, Carla Tortorella, Ruggero Capra, Massimiliano Mirabella, Claudio Gasperini	39
5	PMS24 Multiple Sclerosis Disease Progression Simulation: The Importance of Specific DATA for Progressive and Relapsing Course 2020 ·Value in Health ·Paolo Angelo Cortesi, Carla Fornari, Ruggero Capra, (unknown), Francesco Patti, LG Mantovani	1
6	Four cases of natalizumab-related PML: a less severe course in extended interval dosing? 2019 ·Neurological Sciences ·Cristina Scarpazza, Nicola De Rossi, (unknown), (unknown), Simonetta Gerevini, Ruggero Capra	19
7	Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate 2019 ·Multiple Sclerosis Journal ·Cristina Scarpazza, Alessio Signori, Mirco Cosottini, Maria Pia Sormani, Simonetta Gerevini, Ruggero Capra	13
8	Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy 2017 ·Viral Immunology ·Francesca Rossi, Luca Prosperini, Nicola De Rossi, Ruggero Capra, Daniela Rivanera, Xiuhong Li, Paola Cinque, (unknown), Carlo Pozzilli, Raphael P. Viscidi	1
9	Rituximab Treatment of Highly Active Multiple Sclerosis (MS) After Natalizumab-Related Progressive Multifocal Leukoencephalopathy (PML) (P6.166) 2016 ·Neurology ·Cinzia Cordioli, Nicola De Rossi, Sarah Rasia, Giuseppe Santuccio, Ruggero Capra	2
10	Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads 2015 ·Multiple Sclerosis Journal ·Luca Prosperini, Pietro Annovazzi, Marco Capobianco, Ruggero Capra, Fabio Buttari, Claudio Gasperini, Simonetta Galgani, Claudio Solaro, Diego Centonze, Antonio Bertolotto, Carlo Pozzilli, Angelo Ghezzi	19
11	A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study 2015 ·Frontiers in Neurology ·Flavia Mattioli, Chiara Stampatori, Fabio Bellomi, Maura Danni, (unknown), Antonio Uccelli, Matteo Pardini, Giuseppe Santuccio, (unknown), (unknown), (unknown), Raffaella Clerici, (unknown), Cristina Montomoli, Barbara Corso, Ruggero Capra	27
12	Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy 2014 ·Journal of Neuroimmunology ·Federico Serana, Marco Chiarini, Alessandra Sottini, Diego Bertoli, Viviana Giustini, (unknown), Luigi Caimi, Ruggero Capra, Luisa Imberti	5
13	Patterns of regional gray matter and white matter atrophy in cortical multiple sclerosis 2014 ·Journal of Neurology ·Laura Parisi, Maria A. Rocca, Flavia Mattioli, Gianna Carla Riccitelli, Ruggero Capra, Chiara Stampatori, Fabio Bellomi, Massimo Filippi	5
14	MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients 2014 ·PLoS ONE ·Federico Serana, Luisa Imberti, Maria Pia Amato, Gıancarlo Comı, Claudio Gasperini, Angelo Ghezzi, Vittorio Martinelli, Leandro Provinciali, (unknown), Stefano Sotgiu, S. Stecchi, Michele Vecchio, Mauro Zaffaroni, Cinzia Cordioli, Ruggero Capra	15
15	Assessing executive function with the D-KEFS sorting test: normative data for a sample of the Italian adult population 2014 ·Neurological Sciences ·Flavia Mattioli, Chiara Stampatori, Fabio Bellomi, Cristina Scarpazza, P. Gallì, (unknown), Barbara Corso, Cristina Montomoli, Claudia Niccolai, Benedetta Goretti, Maria Pia Amato, (unknown), (unknown), Monica Falautano, Ruggero Capra	19
16	Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients 2009 ·Endocrine Metabolic & Immune Disorders - Drug Targets ·Alessandra Sottini, Ruggero Capra, Federico Serana, Marco Chiarini, Luigi Caimi, Luisa Imberti	13
17	Modulation of IFNAR1 mRNA expression in multiple sclerosis patients 2008 ·Journal of Neuroimmunology ·Federico Serana, Alessandra Sottini, Claudia Ghidini, Cinzia Zanotti, Ruggero Capra, Cinzia Cordioli, Luigi Caimi, Luisa Imberti	12
18	A multicentre longitudinal study comparing the sensitivity of monthly enhanced MRI after single and triple dose gd-DTPA injection for monitoring disease activity in multiple sclerosis 1997 ·The Italian Journal of Neurological Sciences ·Massimo Filippi, (unknown), Maria Pia Sormani, Claudio Gasperini, Ruggero Capra, Tarek Yousry, Vittorio Martinelli, Stefano Bastianello, (unknown), (unknown), Gıancarlo Comı	1
19	Immunological and gadolinium-DTPA MRI evaluation of relapsing remitting multiple sclerosis 1992 ·Acta Neurologica Scandinavica ·Ruggero Capra, (unknown), (unknown), L.A. Vignolo, (unknown), Paolo Airó, Roberto Cattaneo, Roberto Gasparotti, Rita Moretti	9
20	[The treatment of periarthritis of the shoulder with hydrocortisone acetate; experience in 50 cases]. 1953 ·PubMed ·A Robecchi, Ruggero Capra	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact